Gestational diabetes mellitus (GDM) and preeclampsia are two common complications of pregnancy. Their prevention and treatment are interesting issues in the field of obstetrics. Both of these conditions are associated with a high risk of pregnancy complications. Metformin is an oral hypoglycemic agent which is shown to be effective in management of GDM (1, 2). Although several years ago, metformin had no role in management of GDM because of uncertainties about the possibility of fetal side effects, recently increasing evidence is reported about its safety in pregnancy and also its effectiveness in management of GDM (3, 4). Metformin had been used in patients with polycystic ovarian syndrome (5-7), then its use was developed to patients with GDM. A recent paper has reported its role in decreasing weight gain in obese pregnant women without diabetes mellitus (8). In this paper, the authors highlighted the role of metformin in decreasing the rate of preeclampsia (8). However, similar results are reported by other researchers, but current available evidence is conflicting (1, 9).
TYPE OF ARTICLE: LETTER TO EDITOR
Dear Editor, Gestational diabetes mellitus (GDM) and preeclampsia are two common complications of pregnancy. Their prevention and treatment are interesting issues in the field of obstetrics. Both of these conditions are associated with a high risk of pregnancy complications. Metformin is an oral hypoglycemic agent which is shown to be effective in management of GDM (1, 2). Although several years ago, metformin had no role in management of GDM because of uncertainties about the possibility of fetal side effects, recently increasing evidence is reported about its safety in pregnancy and also its effectiveness in management of GDM (3, 4). Metformin had been used in patients with polycystic ovarian syndrome (5-7), then its use was developed to patients with GDM. A recent paper has reported its role in decreasing weight gain in obese pregnant women without diabetes mellitus (8). In this paper, the authors highlighted the role of metformin in decreasing the rate of preeclampsia (8). However, similar results are reported by other researchers, but current available evidence is conflicting (1, 9).
In a recent paper, Brownfoot et al. highlighted the role of metformin in prevention and treatment of preeclampsia (10) and some possible mechanisms of the role of metformin in preeclampsia. Results of this study showed reduction of soluble fms-like tyrosine kinase 1 and soluble endoglin secretion by metformin, from endothelial and placental tissues. These mechanisms are involved in the process of preeclampsia, and metformin had the potential for treatment and prevention of preeclampsia by the mentioned mechanisms (10). Some other mechanisms are believed to play a preventive role of metformin in preeclampsia. Decreased expression of vascular cell adhesion molecule 1 (VCAM-1) in endothelial cells are another mechanism of prevention of preeclampsia. Vascular cells and angiogenesis are other important factors in pathophysiology of preeclampsia. Metformin improves angiogenesis and vasodilation of omentum vessels (10).
We recommend randomized controlled trials on the role of metformin in preeclampsia. Metformin side effects, including lactic acidosis, which affect both mother and fetus, should be carefully monitored. The rate of lactic acidosis is low in patients using metformin, and this condition is reported in patients using doses higher than 3gr per day of metformin. In patients with hepatic impairment, it should be used cautiously, because renal impairment is a risk factor for lactic acidosis.
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